Ifosfamide, carboplatin, and etoposide in combination for induction and high-dose chemotherapy: focus on breast cancer and lymphoma.
Fields
K K
KK
Department of Internal Medicine, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa.
Elfenbein
G J
GJ
Saleh
R A
RA
Zorsky
P E
PE
Janssen
W E
WE
Perkins
J B
JB
Saleh
T G
TG
Piazza
J T
JT
Kronish
L E
LE
Machak
M C
MC
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use / Q000633:toxicity; D001943:Breast Neoplasms / Q000188:drug therapy*; D016190:Carboplatin / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005047:Etoposide / Q000008:administration & dosage*; D005260:Female; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage*; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D016019:Survival Analysis
D005047:Etoposide; D016190:Carboplatin; D007069:Ifosfamide